BRCA genes: lessons learned from experimental and clinical cancer

How do real tumors become resistant to cisplatin?

(2011) Piet Borst et al.   CELL CYCLE

Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy

(2010) Abhimanyu S. Paraskar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ovarian Low-grade and High-grade Serous Carcinoma

(2009) Russell Vang et al.   ADVANCES IN ANATOMIC PATHOLOGY

BRCA-deficient animal models and cisplatin resistance

(2009) F. Muggia   ANNALS OF ONCOLOGY

Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis

(2009) K Levanon et al.   ONCOGENE

Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer

(2008) Franco Muggia   GYNECOLOGIC ONCOLOGY

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

The cell of origin of ovarian epithelial tumours

(2008) Louis Dubeau   LANCET ONCOLOGY